Cytosorbents’ (CTSO) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the medical research company’s stock.

A number of other equities research analysts have also issued reports on the company. StockNews.com began coverage on Cytosorbents in a research note on Saturday, December 28th. They set a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO opened at $0.94 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $51.21 million, a price-to-earnings ratio of -2.60 and a beta of 0.58. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.59. The firm’s 50-day moving average is $0.92 and its 200 day moving average is $1.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CTSO. Sargent Investment Group LLC lifted its holdings in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the period. Atomi Financial Group Inc. purchased a new stake in Cytosorbents in the third quarter worth about $51,000. Finally, Geode Capital Management LLC lifted its stake in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the period. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.